Last updated: 11/03/2018 22:33:39

A Study to investigate the impact of a multiple micronutrient (MMN) beverage powder on vaccine response in school children

GSK study ID
204476
Clinicaltrials.gov ID
NCT02551627
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Impact of a multiple micronutrient (MMN) beverage powder on vaccine response in school children (7-10yrs; inclusive) in Bangladesh: a randomised, double blind controlled trial
Trial description: This will be a double blind, two-arm, parallel-group, stratified for gender, randomised, controlled study in participants aged 7-10 years (yrs). The aim of the study is to test the hypothesis that MMN fortified beverage may help improve immunity outcomes as assessed through vaccine response in 7-10 yrs old school participants.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Allocation:
Randomized
Primary outcomes:

Vaccine response test

Timeframe: 18 weeks

Secondary outcomes:

Absolute vibriocidal antibody titer

Timeframe: 18 weeks

Change from baseline in nutrional biochemistry

Timeframe: 18 weeks

Interventions:
  • Dietary supplement: Test Product
  • Dietary supplement: Control
    • Enrollment:
    0
    Primary completion date:
    2017-08-06
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Growth and Development
    Product
    GSK3129091
    Collaborators
    Not applicable
    Study date(s)
    October 2016 to June 2017
    Type
    Interventional
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    7 - 10 years
    Accepts healthy volunteers
    Yes
    • Understanding and willingness to participate in the study as demonstrated by participants’ parents and/or Legally acceptable representatives (LARs) voluntary written informed consent, participants’ written assent
    • Participants aged between 7-10 yrs, inclusive
    • Children in Care (CiC)
    • Known or suspected intolerance or hypersensitivity to the study material or any of their stated ingredients or any known food allergies like peanut allergy, gluten allergy or lactose intolerance
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Understanding and willingness to participate in the study as demonstrated by participants’ parents and/or Legally acceptable representatives (LARs) voluntary written informed consent, participants’ written assent
    • Participants aged between 7-10 yrs, inclusive
    • Good general and mental health
    • Participants with Z-scores of BMI for age of ≥-3 to ≤+1
    Exclusion criteria:
    • Children in Care (CiC)
    • Known or suspected intolerance or hypersensitivity to the study material or any of their stated ingredients or any known food allergies like peanut allergy, gluten allergy or lactose intolerance
    • Participant who has already been administered cholera vaccine in any form prior to this study and any known contra-indication to oral cholera vaccine
    • Participant who consumed any antibiotics during the week prior to the first dose of study vaccination until the end of the study
    • Severe anemia (Hb < 8 g/dL), recent history (2 months) of serious infections, injuries and/or surgeries
    • Participant consuming nutritional supplement and/or health food drinks on regular basis (≥ 3 times a week) in last 3 months
    • Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder
    • Participants likely to move out of geographical range of the study within study duration
    • Child of an employee of the sponsor or the study site or members of their immediate family, sibling of participant already enrolled in the study
    • Previous participation in this study, in another clinical study or receipt of an investigational drug within 30 days of screening visit; participation in any nutritional study or didactic nutritional education in last 6 months of the screening visit

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    Other
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website